PTC THERAPEUTICS, INC.
PTCT· Nasdaq· Pharmaceutical Preparations
- Market cap
- –
- P/FCF
- –
- EV/Sales
- –
- FCF margin
- 40.6%
- ROIC, 5 yr avg
- –
- Revenue, 5 yr CAGR
- +35.4%
We record prices for the companies we cover; PTCT is not one of them yet.
Company statistics
Profile · FY2025
- Market cap
- –
- Enterprise value
- –
- Diluted shares
- 88.3M
- Revenue
- $1.7B
- Free cash flow
- $702.3M
- Owner earnings
- $627.8M
Valuation · FY2025
- P/E
- –
- P/FCF
- –
- P/Owner earnings
- –
- EV/Sales
- –
- EV/FCF
- –
- P/B
- –
Margins · FY2025
- Gross
- –
- Operating
- 50.1%
- Net
- 39.4%
- Free cash flow
- 40.6%
- Owner earnings
- 36.3%
- Stock pay
- 4.3%
Returns
- ROIC, FY2025
- –
- ROIC, 5 yr avg
- –
- ROE, FY2025
- –
- ROE, 5 yr avg
- –
Growth (CAGR)
- Revenue, 3 yr
- 35.3%
- Revenue, 5 yr
- 35.4%
- Revenue, 9 yr
- 40.2%
- Diluted EPS, 3 yr
- –
- Diluted EPS, 5 yr
- –
- Diluted EPS, 9 yr
- –
- Free cash flow, 3 yr
- –
- Free cash flow, 5 yr
- –
- Free cash flow, 9 yr
- –
Financial health · FY2025
- Cash and investments
- $1.9B
- Total debt
- –
- Net cash
- –
- Debt/Equity
- –
- Debt/FCF
- –
Shareholder returns · FY2025
- Dividend yield
- –
- Payout ratio
- –
- Buyback yield
- –
- Shareholder yield
- –
- Share count, 5 yr
- 6.0%
Financials: ten years from the 10-Ks
Revenue
$1.7B
+40.2% a year over 9 years
FY2016FY2025
Margins
Operating50.1%Net39.4%
FY2025
FY2016FY2025
Free cash flow and owner earnings
Free cash flow$702.3MOwner earnings$627.8M
FY2025
FY2016FY2025
Diluted shares
88.3M
+50.0% over 9 years, net dilution
FY2016FY2025
Net cash
–
$854.3M more cash than debt
FY2016FY2025
Every figure, year by year
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| The business | ||||||||||
| Revenue | $82.7M | $194.4M | $264.7M | $307.0M | $380.8M | $538.6M | $698.8M | $937.8M | $806.8M | $1.7B |
| Revenue growth | 124.9% | 135.0% | 36.2% | 16.0% | 24.0% | 41.4% | 29.7% | 34.2% | -14.0% | 114.5% |
| Gross margin | – | – | – | – | – | – | – | – | – | – |
| Operating margin | -159.7% | -33.1% | -43.7% | -78.6% | -113.4% | -69.5% | -64.0% | -46.9% | -37.5% | 50.1% |
| Net income | -$142.1M | -$79.0M | -$128.1M | -$251.6M | -$438.2M | -$523.9M | -$559.0M | -$626.6M | -$363.3M | $682.6M |
| Net margin | -171.8% | -40.6% | -48.4% | -82.0% | -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
| Diluted EPS | – | – | – | $-4.27 | $-6.64 | $-7.43 | $-7.79 | $-8.37 | $-4.73 | $7.78 |
| Return on invested capital? | – | – | – | – | – | – | – | – | – | – |
| Cash | ||||||||||
| Operating cash flow | -$103.6M | -$10.1M | -$27.6M | -$98.6M | -$194.1M | -$251.3M | -$356.7M | -$158.4M | -$107.7M | $711.2M |
| Capital expenditure | $1.8M | $3.1M | $7.1M | $13.8M | $17.8M | $28.2M | $32.0M | $28.4M | $6.5M | $8.9M |
| Free cash flow | -$105.3M | -$13.2M | -$34.7M | -$112.4M | -$211.9M | -$279.5M | -$388.7M | -$186.9M | -$114.2M | $702.3M |
| Stock-based compensation | $35.0M | $30.6M | $33.3M | $42.1M | $70.3M | $103.5M | $110.3M | $101.6M | $74.6M | $74.5M |
| Owner earnings? | -$140.4M | -$43.7M | -$68.0M | -$154.5M | -$282.2M | -$383.1M | -$499.0M | -$288.5M | -$188.8M | $627.8M |
| Free cash flow per share | – | – | – | $-1.91 | $-3.21 | $-3.97 | $-5.42 | $-2.50 | $-1.49 | $7.95 |
| Capital allocation | ||||||||||
| Dividends paid | – | – | – | – | – | – | – | – | – | – |
| Share repurchases | – | – | – | – | – | – | – | – | – | – |
| Diluted shares | – | – | – | 58.9M | 66.0M | 70.5M | 71.7M | 74.8M | 76.8M | 88.3M |
| Share count change? | – | – | – | – | 12.2% | 6.7% | 1.8% | 4.3% | 2.7% | 14.9% |
| Balance sheet | ||||||||||
| Cash and equivalents | $58.3M | $111.8M | $169.5M | $288.0M | $208.8M | $189.7M | $279.8M | $594.0M | $779.7M | $984.6M |
| Short-term investments | $173.3M | $79.5M | $58.1M | $398.5M | $894.8M | $583.7M | $130.9M | $282.7M | $360.0M | $960.7M |
| Total debt | $98.2M | $145.0M | $153.0M | $313.9M | $309.1M | $431.4M | $571.7M | $284.2M | $285.4M | – |
| Net debt | -$133.4M | -$46.3M | -$74.6M | -$372.7M | -$794.5M | -$341.9M | $161.0M | -$592.5M | -$854.3M | – |
| Shareholders' equity | $119.6M | $156.4M | $350.7M | $594.3M | $482.0M | $1.4M | -$347.1M | -$818.6M | -$1.1B | -$205.3M |
Latest filings
| 2026-10-29 | 10-Q | Quarterly report |
| 2026-10-29 | 8-K | Earnings release |
| 2026-07-30 | 10-Q | Quarterly report |
| 2026-07-30 | 8-K | Earnings release |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Earnings release |
| 2026-04-20 | DEF 14A | Proxy statement |
| 2026-02-19 | 10-K | Annual report |
| 2026-02-19 | 8-K | Earnings release |
| 2026-01-12 | 8-K | Earnings release |
More from our coverage
- MSFTPlatforms8.4MicrosoftThe most entrenched software franchise in the enterprise, now spending its cash flow on AI capacity; a great business we would own with a margin of safety, not at any price.Base value $410.29
- NVDAAI infrastructure8.4NVIDIAThe best business in technology at the top of its cycle: the moat is CUDA as much as silicon, but today's margins are a peak, not a floor.Base value $104.32
- AAPLHardware7.6AppleOne of the highest-quality businesses in the world growing in the low single digits; the price usually assumes more growth than the numbers show.Base value $134.27
- GOOGLPlatforms7.4AlphabetSearch pays for everything, and AI is both its biggest threat and its biggest opportunity; the price has to allow for search being worth less than it was.Base value $209.60
- NOWSoftware7.4ServiceNowA rare enterprise platform still growing above 20% with high retention; the free cash flow is real but stock pay takes a large share of it.Base value $189.13
- ADBESoftware7.4AdobeSuperb margins and a shrinking share count, priced for decline; the question is whether AI makes Adobe's tools more valuable or makes them unnecessary.Base value $449.35
